862 related articles for article (PubMed ID: 22576456)
1. Immunotherapy of cancer in 2012.
Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S
CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456
[TBL] [Abstract][Full Text] [Related]
2. The expanding role of immunotherapy.
Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunology top 10 list.
Finn OJ
Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
[No Abstract] [Full Text] [Related]
5. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.
Roviello G; Polom K; Petrioli R; Marano L; Marrelli D; Paganini G; Savelli V; Generali D; De Franco L; Ravelli A; Roviello F
Tumour Biol; 2016 Jan; 37(1):127-40. PubMed ID: 26566626
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
7. Promising early results for immunotherapy-antiangiogenesis combination.
Garber K
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421345
[No Abstract] [Full Text] [Related]
8. Cancer immunology and melanoma immunotherapy.
Linck RDM; Costa RLP; Garicochea B
An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against tumour blood vessels in colorectal cancer.
Ferguson HJ; Wragg J; Ismail T; Bicknell R
Eur J Surg Oncol; 2014 Feb; 40(2):133-6. PubMed ID: 24388410
[No Abstract] [Full Text] [Related]
10. The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors.
Demlova R; Valík D; Obermannova R; ZdraŽilová-Dubská L
Physiol Res; 2016 Dec; 65(Suppl 4):S455-S462. PubMed ID: 28006927
[TBL] [Abstract][Full Text] [Related]
11. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
Lee J; Kefford R; Carlino M
Immunotherapy; 2016 Jun; 8(6):733-46. PubMed ID: 27197541
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.
Issafras H; Fan S; Tseng CL; Cheng Y; Lin P; Xiao L; Huang YJ; Tu CH; Hsiao YC; Li M; Chen YH; Ho CH; Li O; Wang Y; Chen S; Ji Z; Zhang E; Mao YT; Liu E; Yang S; Jiang W
PLoS One; 2021; 16(12):e0257972. PubMed ID: 34972111
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of tumor by targeting angiogenesis.
Hou J; Tian L; Wei Y
Sci China C Life Sci; 2004 Dec; 47(6):545-52. PubMed ID: 15620111
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Sweis RF; Luke JJ
Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
[TBL] [Abstract][Full Text] [Related]
15. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for gastrointestinal malignancies.
Toomey PG; Vohra NA; Ghansah T; Sarnaik AA; Pilon-Thomas SA
Cancer Control; 2013 Jan; 20(1):32-42. PubMed ID: 23302905
[TBL] [Abstract][Full Text] [Related]
17. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody therapy.
O'Mahony D; Bishop MR
Front Biosci; 2006 May; 11():1620-35. PubMed ID: 16368542
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
Johnson BF; Clay TM; Hobeika AC; Lyerly HK; Morse MA
Expert Opin Biol Ther; 2007 Apr; 7(4):449-60. PubMed ID: 17373897
[TBL] [Abstract][Full Text] [Related]
20. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.
Kaumaya PT; Foy KC
Future Oncol; 2012 Aug; 8(8):961-87. PubMed ID: 22894670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]